Strontium ranelate: a new paradigm in the treatment of osteoporosis
Authors:
- Jean-Yves ReginsterJRJean-Yves Reginster
- Marie-Paule LecartMLMarie-Paule Lecart
- Rita DeroisyRDRita Deroisy
- Christian LousbergCLChristian Lousberg
- 1 July 2004
- journal article
- clinical trial
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 13 (7) , 857-864
Abstract
In vitro, strontium ranelate increases collagen and non-collagenic protein synthesis by mature osteoblast-enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated osteoclast, a preincubation of bone slices with strontium ranelate induced a dose-dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. The drug was administered in 160 early postmenopausal women, in a 24-month, double-blind, placebo-controlled, prospective randomised study. At the conclusion of the study, the percentage variation of lumbar bone mineral density (BMD) from baseline was significantly different in the group receiving strontium ranelate 1000 mg/day as compared with placebo (+5.53 versus -0.75%, respectively). Increase in total hip and neck BMD averages were 3.2 and 2.5%, respectively. The effect of strontium ranelate in postmenopausal women with established osteoporosis was assessed during a multinational, prospective, double-blind, randomised, placebo-controlled trial. Strontium ranelate (500, 1000, 2000 mg/day) or placebo were given to 353 Caucasian women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study, the annual increase in lumbar BMD of the group receiving strontium ranelate 2000 mg was 7.3% (p < 0.001). A significant increase in bone alkaline phophatase (p = 0.002) over a 6-month period and a significant decrease in N-telopeptide crosslinks (p = 0.004) throughout the 2-year period were seen in the group receiving 2000 mg of strontium ranelate. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. Bone histomorphometry showed no mineralisation defects. The primary analysis of the SOTI study, evaluating the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patients experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture in the group treated with strontium ranelate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture was also demonstrated in the patients treated for > or = 18 months.Keywords
This publication has 10 references indexed in Scilit:
- The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 2004
- S12911-2 reduces bone loss induced by short-term immobilization in ratsBone, 2003
- S 12911-2 Inhibits Osteoclastic Bone Resorption In VitroJournal of Bone and Mineral Research, 2003
- Prevention of Early Postmenopausal Bone Loss by Strontium Ranelate: The Randomized, Two-Year, Double-Masked, Dose-Ranging, Placebo-Controlled PREVOS TrialOsteoporosis International, 2002
- Mechanisms of Action and Therapeutic Potential of Strontium in BoneCalcified Tissue International, 2001
- Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis)Bone, 2001
- Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administrationJournal of Bone and Mineral Research, 1996
- The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitroBone, 1996
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993
- An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient ratsJournal of Bone and Mineral Research, 1993